Immunoclin Limited
- Active
- Micro
- 26 years
- 2 employees
- £19,768 (cur assets)
- 0-1m
- Real address
- 3 directors
- No owners
- London
Two conditions of three:
1.Turnover < £632,000
2.Balance sheet total < £316,000
3.Average number of employees < 10
Field of Operation
Summary
Immunoclin Limited is a private limited company registered in England/Wales with the registration number 03914021. The company was founded twenty six years ago on January 26, 2000, and registered at NW1 0NH, London, 2 Royal College Street. The address is probably real as only three companies are registered at the same address. Its status is active. The company operates in the professional services, the processing & manufacturing, the pharma, the technical testing, the biotechnology r&d, the vaccines, medicaments, diagnostic substances, biotech etc industries. Officially, it has not published owners as their shares less than twenty five percent for each shareholder. It has three directors, and two employees.
It's a micro company as it met two conditions of three: turnover less than £632,000, balance sheet total less than £316,000, employees less than 10. The last reported current assets is £19,768.
WARNING: The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.
Ports, countries, transport, and price/kg were calculated by CorpSignals; non-official data, may contain errors.
Managers
-
Individual
- 12 years
-
Resident of United Kingdom
-
Individual
- 23 years
- 3
-
Resident of United Kingdom
-
Individual
- 23 years
-
Resident of United Kingdom
Last reports
The latest confirmation statement submitted ten months ago.
Last news
-
Micro company accounts made up to 2025-02-28Download 8 pages pdf report
-
Confirmation statement made on 2025-07-18 with no updatesDownload 3 pages pdf report
-
Unaudited abridged accounts made up to 2024-02-29Download 10 pages pdf report
FAQ about Immunoclin Limited
Looking for leads in the UK?
Book a demo—see how CorpSignals can help you find UK leads.